Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I tried finding sales data on it, and if I did math correctly, it is about $1.5B in US Sales over the last year. Wouldn't need much market share for some solid revenue numbers. Again, this is only if I was looking at the data correctly. Anyone else feel free to offer your conjectures.
I inferred from ID that he hoped that he could exercise the shares by Sept because that would mean the pps would be above the grant price. I don't think the pop in price and the actual exercising of options were related on his scenario. Just wishful thinking! That was my take anyway
Yes, but wouldn't that be diluting by less than 2% of the float? I would take an additional 385,000 shares in the float in trade for 40% pps pop. I see IDs point.
POZN filed with the FDA on the same date as IGXT (3/27) and they seemed to be able to update shareholders on 5/29 that the FDA accepted their submission. What is the problem here?
As I sit and watch my money do nothing this past month, I ponder what could have been if I had used the funds to snag up VNDA at $4.70.
I agree Gary. Did you see the IGXT twitter update today? LIsts 6/10/13 as an FDA catalyst date. Could be playing into today's volume.
I saw that bid sitting at .63 earlier in the day. Nice to see the bid price move up.
We're at $0.70 on Toronto Exchange....with ask at .73!
Only based on past years...but usually around the May 10th - 15th timeframe.
I do not think this was revealed before. Quite a nice surprise in my opinion.
OTC Markets website.....anyone else having trouble with otcmarkets.com today?
Interesting trading the last few days.....Anyone else surprised at the 31K share bid @ .60 ?
The new presentation is available as well on the Roth Capital Conference site. Nothing really new on it......but revenue projections ha ven't changed (including the PAR estimated revenue).
Roth Capital Conference Webcast link - for those of you who may be interested in watching. Looks like you need to register to watch but minimal info needed:
http://wsw.com/webcast/roth27/igxt/
Valuation on this is re-donkulous. It is trading for basically the potential value of milestone payments from Forfivo.....niothing else....no value from pipeline, patents, IP, assests, etc.....
Did you get them?? I see we touched .45
OK.....not sure what this is???? Weird find....if anyone cares to take a stab at commenting...I'd appreciate it. I'm not sure what to think. It's a video on YouTube of some guy ranting about Forfivo.
Intelgenx hiring....I currently lack the experience they are looking for but thought I would post for other investors who may want to become employees :)
http://www.linkedin.com/jobs?viewJob=&jobId=4706293&trk=jobs_seeking_view_job&goback=.vjs_4834787_*2_*2_*2_false_*2
WTH - I realize the lack of news is keeping the price down.....but even with that taken into account the valuation on this stock is getting ridiculous.
RedHill Milestone Payments/Royalties
Not sure if this has been psoted before, sorry if it is a duplicate. Came across the licensing agreement with Red Hill and thought it gave some good info.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204%2D12%2D069612%2Etxt&FilePath=%5C2012%5C12%5C26%5C&CoName=REDHILL+BIOPHARMA+LTD%2E&FormType=20FR12B&RcvdDate=12%2F26%2F2012&pdf=
License Agreement for RHB-103
On August 26, 2010, we entered into a joint development and commercialization agreement with IntelGenx Corp. under which IntelGenx Corp. granted us a worldwide, exclusive and perpetual license to use its rights in patents and know-how relating to a triptan formula based on the VersaFilm TM technology and which we call RHB-103.
The license includes the right to grant sublicenses. The license covers the co-developing, selling, offering for sale and importing the product for all indications, including, but not limited to, acute treatment of migraine attacks with or without an aura and all other therapeutic, diagnostic, and other human /or animal uses.
The license provides that IntelGenx Corp. reserves the right to grant licenses to manufacture the product, subject to the approval of a steering committee. The agreement further limits our right to grant sublicenses by requiring that we give prior notice to IntelGenx Corp. of the identity of any proposed sub-licensee and provide IntelGenx Corp. with information regarding the main elements of the proposed sublicense agreement. If IntelGenx Corp. objects to a sublicense, the proposed sublicense will be presented for the approval of a steering committee.
39
Pursuant to the agreement, the parties agreed on joint product development activities. Accordingly, IntelGenx Corp. agreed to devote sufficient resources (subject to the approved budget in the agreement) in order to conduct clinical trials and file an application with the U.S. Food and Drug Administration for marketing of the product, and we agreed to finance the balance of the development in the amount of approximately $849,000, subject to deviations of 10%.
The joint development of the product is to be conducted through a steering committee, comprised of an equal number of members appointed by us and IntelGenx Corp. The committee is charged with supervising progress of our research and development efforts, reporting on possible delays and deciding on required revisions in the plan. IntelGenx Corp. has the deciding vote in any vote relating to issues of development, regulation and manufacture, while we have the deciding vote in any vote relating to issues of licensing, commercialization and collaborations.
In consideration for the license, we made up-front and milestone payments in the aggregate amount of $600,000 and we are required to make additional milestone payments of up to $700,000 as follows:
· $200,000 upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and
· $500,000 upon receipt of U.S. Food and Drug Administration marketing approval for the product.
In addition, we are required to make royalty payments to IntelGenx Corp. of 20% of net sales if the product is marketed by us and 60% of the first $2 million of net sublicense fees, and 40% of net sublicensing fees thereafter, in if the product is marketed by sublicensees. However, if we bear the regulatory costs in a sublicense arrangement, royalties will be 20% of net sublicense fees until we recover these costs, plus 10% interest, and if IntelGenx Corp. bears such costs, royalties will be 70% of net sublicense fees.
The agreement provides that all intellectual property developed or to be developed exclusively by IntelGenx Corp. will belong exclusively to IntelGenx Corp. and will be licensed to us, and the intellectual property to be developed or financed jointly by IntelGenx Corp. and us will be jointly owned by us and IntelGenx Corp., and each party may make use of such joint intellectual property for uses not competing with either the product or the other party.
The agreement is of unlimited duration and will remain in force until terminated in accordance with its terms. Either party may terminate the agreement if (i) the other party is in material breach and does not cure within ninety (90) days; or (ii) a bankruptcy or liquidation event occurs with respect to the other party. This agreement also provides that we may terminate the agreement for convenience upon providing thirty (30) days written notice to IntelGenx Corp.
Along the same lines....it appears there hasn't been any trades on the Canadian Exchange since last Friday.
Just watched it and I agree spec. One factor that still is a big question is the Par deal. But based on what we have right now, the $1.00 price is about a 10 PE on $4M in earnings. I'm hoping we can get a little more than that just based on growth estimates.
One Med Presentation link:
http://www.onemedplace.com/database/list/cid/14099
Video is on this page. Haven't had chance to view yest, but slides appear to have been updated.
Considering the Holiday...the action isn't too bad today. Not a lot of volume, but I've been watching the level II quotes you can see the bid/ask action is more than I've seen recently.
I agree. And who traded 100 shares (first trade this morning). I sure hope nobody would pay commission on a $62 transaction.
Merry Christmas to all longs!
3000 on the ask at 65....then nothing until 69
IGXTIntelGenx Technologies Corp. Common Stock DAD: Dorsey & Whitney LLP OTCQX U.S.
0.640.01 (1.59%)
Real-Time Best Bid & Ask
0.6401 / 0.645(30000 x 1000)Previous Close
MPID Ask Price Size Date/Time
NITE 0.645 1000 11/19
UBSS 0.65 2000 13:21
CDEL 0.65 1000 12:05
MERQ 0.69 1000 11/16
CSTI 0.699 2500 10:46
VERT 0.70 30000 09:30
Sounds like the next few months will be packed with good news. We should have the PAR deal revealed in December, NDA filing for Migraine in 1Q, and first sales figures for Forfivo in Feb as well. Load up the shares!
10-Q is out. http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8570194.
Still reading it....but found this chunk of info under Revenue on pg. 13:
In February 2012 we received a $1.0 million upfront payment under our licensing agreement with Edgemont Pharmaceuticals for our FDA approved product Forfivo XL™. The upfront payment has been recorded as deferred license revenue and will be recognized as revenue on a straight-line basis until December 2015, which is the estimated minimum time period that the product could retain market exclusivity. Subsequent to the end of the third quarter, on October 9, 2012, we announced that Forfivo XL™ had been commercially launched by Edgemont in the USA. As a result, we will start to recognize the upfront payment as revenue commencing in the fourth quarter of 2012. In addition, the commercial launch of Forfivo XL™ triggered the next milestone payment, which will be fully recorded as revenue in the fourth quarter.
Notice the usage of past tense...meaning he is confirming they did receive the milestone (just haven't recorded it)
I am long....but also fear a drop to the upper .50s. I think the next couple days will be important as we have settled back to the 50 day MA. If we can bounce off of that I would have a little more confidence of bouncing back to lower .70s. If we can't hold the 50 day....back to the upper .50s.
Thanks Tobhar. That definitely sums it up nicely. Thanks for the find.
That's what I was thinking as well. I assume we will get at least $4.0M in Q4. That should help with the cash balance.
Milestone Payments - can anyone confirm my "research"? IGXT has received $1.0M of the possible $5.0M in launch milestones from Edgemont (as of 9/30/12) - does that seem correct?
TAGG Reported Revenue - from last 10-Q filed (which was for 2Q)
Our net loss for the six month period ended June 30, 2012 was ($212,668) compared to a net loss of ($139,540) during the six month period ended June 30, 2011 (an increase of $73,128). During the six month periods ended June 30, 2012 and 2011, we did not generate any revenue.
Don't pretend like this is a diamond. Get out now.
IMS Data - does anyone know of any IMS numbers so far for the launch of Forfivo? It would be nice to get a glimpse as to how the launch is going!
OK...this is good news. But can anyone answer me this? How did they buy 80,000 shares on 10/11 at $0.6677 when the low trade for that day was $0.68?
Nice Seeking Alpha article this morning:
http://seekingalpha.com/instablog/192072-ccamire/1158121-intelgenx-moving-to-the-next-stage
Thanks! Just happy to spread the word to fellow longs.
Forfivo Available Now - it is official folks. The webiste is now open for business!
http://www.forfivoxl.com/
Positive comments on IGXT - TEVA's loss is our gain.
http://www.pharmaintellect.com/2012/10/withdrawal-of-tevas-budeprion-xl-300.html